Anne S. Tsao

55.6k total citations · 3 hit papers
217 papers, 6.7k citations indexed

About

Anne S. Tsao is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Anne S. Tsao has authored 217 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 168 papers in Pulmonary and Respiratory Medicine, 105 papers in Oncology and 35 papers in Molecular Biology. Recurrent topics in Anne S. Tsao's work include Lung Cancer Treatments and Mutations (92 papers), Occupational and environmental lung diseases (62 papers) and Pleural and Pulmonary Diseases (43 papers). Anne S. Tsao is often cited by papers focused on Lung Cancer Treatments and Mutations (92 papers), Occupational and environmental lung diseases (62 papers) and Pleural and Pulmonary Diseases (43 papers). Anne S. Tsao collaborates with scholars based in United States, France and Australia. Anne S. Tsao's co-authors include Ignacio I. Wistuba, Waun Ki Hong, Jack A. Roth, Hedy L. Kindler, J. Jack Lee, E. S. Kim, W. K. Hong, Scott M. Lippman, Carol J. Etzel and Farshid Dayyani and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Anne S. Tsao

205 papers receiving 6.5k citations

Hit Papers

Meta-analysis of the impa... 2010 2026 2015 2020 2010 2017 2022 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC)
    2010 388 citations Anne S. Tsao et al. profile →
  2. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
    2017 304 citations Arnaud Scherpereel, Dariusz M. Kowalski et al. profile →
  3. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
    2022 158 citations Solange Peters, Arnaud Scherpereel et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anne S. Tsao United States 42 4.3k 2.6k 1.4k 724 677 217 6.7k
Anil Vachani United States 43 2.7k 0.6× 2.1k 0.8× 1.5k 1.0× 843 1.2× 626 0.9× 193 6.0k
Gregory P. Kalemkerian United States 45 3.9k 0.9× 3.9k 1.5× 2.3k 1.6× 1.2k 1.6× 1.1k 1.6× 179 7.8k
Erik H.F.M. van der Heijden Netherlands 32 3.1k 0.7× 1.7k 0.7× 1.4k 1.0× 922 1.3× 1.1k 1.6× 121 6.1k
Martin J. Edelman United States 52 4.3k 1.0× 4.6k 1.8× 2.0k 1.4× 946 1.3× 690 1.0× 302 8.7k
Gregory A. Masters United States 36 4.0k 0.9× 4.1k 1.6× 1.3k 1.0× 841 1.2× 586 0.9× 127 6.9k
Apar Kishor Ganti United States 37 1.9k 0.4× 2.5k 1.0× 1.8k 1.3× 656 0.9× 406 0.6× 262 5.5k
Brett Hughes Australia 31 2.1k 0.5× 2.3k 0.9× 820 0.6× 696 1.0× 252 0.4× 179 4.4k
Jyoti D. Patel United States 38 3.4k 0.8× 3.9k 1.5× 1.4k 1.0× 832 1.1× 339 0.5× 230 6.1k
Carlos Gil Ferreira Brazil 35 1.4k 0.3× 1.7k 0.7× 1.6k 1.1× 565 0.8× 357 0.5× 179 4.2k
K. Mattson Finland 38 5.6k 1.3× 4.2k 1.6× 1.5k 1.1× 673 0.9× 417 0.6× 178 7.5k

Countries citing papers authored by Anne S. Tsao

Since Specialization
Citations

This map shows the geographic impact of Anne S. Tsao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne S. Tsao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne S. Tsao more than expected).

Fields of papers citing papers by Anne S. Tsao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne S. Tsao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne S. Tsao. The network helps show where Anne S. Tsao may publish in the future.

Co-authorship network of co-authors of Anne S. Tsao

This figure shows the co-authorship network connecting the top 25 collaborators of Anne S. Tsao. A scholar is included among the top collaborators of Anne S. Tsao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne S. Tsao. Anne S. Tsao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Tsao, Anne S., Marianna Koczywas, Jonathan W. Riess, et al.. (2024). S1701: A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 8110–8110. 3 indexed citations
4.
Tsao, Anne S., Marianna Koczywas, Jonathan W. Riess, et al.. (2024). S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma. JTO Clinical and Research Reports. 5(12). 100738–100738. 1 indexed citations
5.
Ahn, M-J., Ibiayi Dagogo‐Jack, Francesco Gelsomino, et al.. (2024). LBA56 Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). Annals of Oncology. 35. S1246–S1247. 2 indexed citations
6.
Riely, Gregory J., Egbert F. Smit, Myung‐Ju Ahn, et al.. (2023). Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.. Journal of Clinical Oncology. 41(16_suppl). 9018–9018. 1 indexed citations
7.
Zalcman, Gérard, Robin Cornelissen, Laurent Greillier, et al.. (2022). LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743. Annals of Oncology. 33. S1438–S1439. 5 indexed citations
8.
Tsao, Anne S., Jeremy Cetnar, Boris Sepesi, et al.. (2021). OA13.01 S1619 A Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and Maintenance for Resectable Pleural Mesothelioma. Journal of Thoracic Oncology. 16(10). S870–S870. 7 indexed citations
9.
Elamin, Yasir Y., Jacqulyne Robichaux, Brett W. Carter, et al.. (2021). Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial. Journal of Clinical Oncology. 40(7). 702–709. 66 indexed citations
10.
Mutti, Luciano, Tobias Peikert, B. W. Robinson, et al.. (2018). Scientific Advances and New Frontiers in Mesothelioma Therapeutics. Journal of Thoracic Oncology. 13(9). 1269–1283. 69 indexed citations
11.
Nelson, David B., David C. Rice, Jiangong Niu, et al.. (2017). Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis. Journal of Clinical Oncology. 35(29). 3354–3362. 58 indexed citations
12.
Zauderer, Marjorie G., Anne S. Tsao, Tao Dao, et al.. (2017). A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. Clinical Cancer Research. 23(24). 7483–7489. 46 indexed citations
13.
14.
Tsao, Anne S., Heather Lin, Brett W. Carter, et al.. (2017). Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 13(2). 246–257. 9 indexed citations
15.
Tsao, Anne S.. (2016). Pembrolizumab for Non–Small-Cell Lung Cancer. Journal watch. 2016. 1 indexed citations
16.
Tsao, Anne S.. (2015). Rociletinib for EGFR-mutated Non–Small-Cell Lung Cancer. Journal watch. 2015. 44 indexed citations
17.
Tsao, Anne S.. (2014). Molecular Profiling for Non–Small-Cell Lung Cancer. Journal watch. 2014. 1 indexed citations
18.
Tsao, Anne S.. (2014). Ceritinib for ALK-Rearranged Non–Small-Cell Lung Cancer. Journal watch. 2014. 86 indexed citations
19.
Tsao, Anne S., Diane Liu, Jack W. Martin, et al.. (2009). Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients with High-Risk Oral Premalignant Lesions. Cancer Prevention Research. 2(11). 931–941. 182 indexed citations
20.
Tsao, Anne S., Timothy J. McDonnell, Stephen Lam, et al.. (2003). Increased Phospho-AKT (Ser473) Expression in Bronchial Dysplasia. Cancer Epidemiology and Prevention Biomarkers. 12(7). 660–664. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anil Vachani Breakdown of academic impact, for papers by Gregory P. Kalemkerian Breakdown of academic impact, for papers by Erik H.F.M. van der Heijden Breakdown of academic impact, for papers by Martin J. Edelman Breakdown of academic impact, for papers by Gregory A. Masters Breakdown of academic impact, for papers by Apar Kishor Ganti Breakdown of academic impact, for papers by Brett Hughes Breakdown of academic impact, for papers by Jyoti D. Patel Breakdown of academic impact, for papers by Carlos Gil Ferreira Breakdown of academic impact, for papers by K. Mattson
Rankless by CCL
2026